Author: American Institute of Steel Construction. Conference
Publisher:
ISBN:
Category : Building, Iron and steel
Languages : en
Pages :

View

Book Description

Author: National Society of Professional Engineers. Professional Engineers in Industry
Publisher:
ISBN:
Category : Engineering
Languages : en
Pages : 98

View

Book Description

Author: American Institute of Steel Construction (New York, N.Y.)
Publisher:
ISBN:
Category :
Languages : en
Pages :

View

Book Description

Author: César A. González Díaz
Publisher: Springer Nature
ISBN: 3030306488
Category : Technology & Engineering
Languages : en
Pages : 1518

View

Book Description
This book gathers the joint proceedings of the VIII Latin American Conference on Biomedical Engineering (CLAIB 2019) and the XLII National Conference on Biomedical Engineering (CNIB 2019). It reports on the latest findings and technological outcomes in the biomedical engineering field. Topics include: biomedical signal and image processing; biosensors, bioinstrumentation and micro-nanotechnologies; biomaterials and tissue engineering. Advances in biomechanics, biorobotics, neurorehabilitation, medical physics and clinical engineering are also discussed. A special emphasis is given to practice-oriented research and to the implementation of new technologies in clinical settings. The book provides academics and professionals with extensive knowledge on and a timely snapshot of cutting-edge research and developments in the field of biomedical engineering.

Author: Wei-Shu Hu
Publisher: Springer
ISBN: 3540340076
Category : Science
Languages : en
Pages : 179

View

Book Description
Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.

Author: National Society of Professional Engineers
Publisher:
ISBN:
Category : Engineering
Languages : en
Pages : 64

View

Book Description

Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :

View

Book Description

Author:
Publisher:
ISBN:
Category : Technology
Languages : en
Pages :

View

Book Description

Author: National Society of Professional Engineers
Publisher:
ISBN:
Category : Engineering
Languages : en
Pages : 60

View

Book Description

Author: Opinion Research Corporation (U.S.)
Publisher:
ISBN:
Category : Engineering
Languages : en
Pages : 114

View

Book Description